The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the separate and combined efficacy of a standardized acupuncture regimen and amitriptyline on the relief of pain due to peripheral neuropathy and on the quality of life of HIV-infected patients.
Both amitriptyline, an antidepressant, and acupuncture, a Chinese medical approach that uses needles to relieve pain, have been used successfully to reduce pain in some people. It is not known how effectively these approaches relieve or reduce pain in patients with peripheral neuropathy secondary to HIV infection.
| Condition | Intervention |
|---|---|
|
HIV Infections Peripheral Nervous System Disease |
Drug: Amitriptyline hydrochloride Drug: Amitriptyline hydrochloride placebo Procedure: Point acupuncture |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Treatment |
| Official Title: | The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients |
- Change in intensity of pain as measured by the daily pain diary and the global pain relief rating [ Time Frame: At Weeks 6 and 14 ] [ Designated as safety issue: No ]
- Change in quality life [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
- Change in neurological status [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
- Permanent discontinuation of study treatment due to treatment failure [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
| Enrollment: | 260 |
| Study Start Date: | November 1994 |
| Study Completion Date: | May 1997 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
|
Drug: Amitriptyline hydrochloride
75 mg oral tablet taken daily
Drug: Amitriptyline hydrochloride placebo
Oral placebo tablet taken daily
Procedure: Point acupuncture
Standardized or alternate acupuncture procedure
|
Detailed Description:
Both amitriptyline, an antidepressant, and acupuncture, a Chinese medical approach that uses needles to relieve pain, have been used successfully to reduce pain in some people. It is not known how effectively these approaches relieve or reduce pain in patients with peripheral neuropathy secondary to HIV infection.
Patients are randomized to receive either standardized point acupuncture or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks. Acupuncture points are located on the lower leg. Patients are evaluated at weeks 6 and 14 and are asked to keep a daily pain diary.
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Antiretroviral therapy.
- Nonsystemic treatment of Kaposi's sarcoma.
- Maintenance with an existing regimen of analgesic medication or herbal treatment.
Concurrent Treatment: Required:
- Acupuncture.
Patients must have:
- HIV infection.
- Lower extremity peripheral neuropathy secondary to HIV infection.
- Pain for at least 2 weeks prior to study entry.
- Life expectancy of at least 6 months.
NOTE:
- Co-enrollment in other experimental protocols is permitted as long as dual participation is allowed in those protocols.
Prior Medication:
Allowed:
- Antiretroviral therapy.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Known allergy to amitriptyline (not applicable for patients at sites using an acupuncture only study design).
- EKG indicating malignant arrhythmia or cardiac conduction disturbances (not applicable for patients at sites using an acupuncture only study design).
- Prison incarceration.
Concurrent Medication:
Excluded:
- Active treatment for an acute opportunistic infection or malignancy (nonsystemic treatment of Kaposi's sarcoma is permitted).
- Other tricyclic antidepressants.
- MAO inhibitors.
Patients with the following prior conditions are excluded (not applicable for patients at sites using an acupuncture only study design):
- History of cardiac disease.
- History of seizure disorder.
Prior Medication:
Excluded within 2 weeks prior to study entry:
- MAO inhibitors.
- Tricyclic antidepressants.
Contacts and Locations| United States, California | |
| Community Consortium of San Francisco | |
| San Francisco, California, United States, 94110 | |
| United States, Colorado | |
| Denver CPCRA / Denver Public Hlth | |
| Denver, Colorado, United States, 802044507 | |
| United States, District of Columbia | |
| Veterans Administration Med Ctr / Regional AIDS Program | |
| Washington, District of Columbia, United States, 20422 | |
| United States, Maryland | |
| Baltimore Trials | |
| Baltimore, Maryland, United States, 21201 | |
| United States, Michigan | |
| Comprehensive AIDS Alliance of Detroit | |
| Detroit, Michigan, United States, 48201 | |
| United States, New Jersey | |
| North Jersey Community Research Initiative | |
| Newark, New Jersey, United States, 071032842 | |
| United States, New Mexico | |
| Partners Research | |
| Albuquerque, New Mexico, United States, 871315271 | |
| United States, New York | |
| Harlem AIDS Treatment Group / Harlem Hosp Ctr | |
| New York, New York, United States, 10037 | |
| Clinical Directors Network of Region II | |
| New York, New York, United States, 10011 | |
| United States, Oregon | |
| Portland Veterans Adm Med Ctr / Rsch & Education Grp | |
| Portland, Oregon, United States, 972109951 | |
| United States, Pennsylvania | |
| Philadelphia FIGHT | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| Study Chair: | Shlay J | |
| Study Chair: | Flaws B |
More Information
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000817 History of Changes |
| Other Study ID Numbers: | CPCRA 022, 11572 |
| Study First Received: | November 2, 1999 |
| Last Updated: | March 30, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Acquired Immunodeficiency Syndrome AIDS-Related Complex Peripheral Nervous System Diseases |
Amitriptyline Pain Acupuncture Therapy |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Nervous System Diseases Peripheral Nervous System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Neuromuscular Diseases Amitriptyline |
Amitriptyline, perphenazine drug combination Antidepressive Agents, Tricyclic Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Adrenergic Uptake Inhibitors Adrenergic Agents Neurotransmitter Agents |
ClinicalTrials.gov processed this record on May 16, 2013